How a University of Bristol spin-off grew to become the first lab customer at Future Space.
Pertinax Pharma were the first company to take up laboratory spaces here at Future Space. Pertinax is a patent-protected, sustained release technology for chlorhexidine, a common antiseptic. It can be used as a filler component of materials for biomedical and other applications, as a component of topical agents, and as a coating for medical devices.
"Moving our operation to Future Space offers us the opportunity to expand our team as we look to develop Pertinax for new applications and markets.”
Stuart Gibson, Chief Financial Officer for Pertinax Pharma
Dr Michele Barbour and her research group at the University of Bristol School of Oral and Dental Sciences have been developing sustained efficacy antimicrobial materials for many years. In April 2015 Pertinax Pharma Ltd was established to commercialise the many and diverse applications of this proprietary CHX technology. Since their ambitious move to Future Space here in Bristol, the company is looking to expand into different markets such as application of the product in wound care and veterinary markets.
More Case Studies
Q&A: Charlotte Bermingham, CTO at Vitamica
“We are working to address the global challenge of antimicrobial resistance…aiming to transform the way clinicians make decisions on antibiotic prescription.”
Watch this space! Local artist Cai Burton comes to Future Space
We catch up with Cai Burton about his work, why art in the workplace is important and his plans for our meeting rooms…
Bristol Robotics Laboratory Hardware Incubator spin-out Homelync takes up residence at Future Space
“What is important to us is growing at a rapid but sustainable rate to ensure we make a real difference to peoples’ lives.”